1. Home
  2. LEGN vs GSAT Comparison

LEGN vs GSAT Comparison

Compare LEGN & GSAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • GSAT
  • Stock Information
  • Founded
  • LEGN 2014
  • GSAT 2003
  • Country
  • LEGN United States
  • GSAT United States
  • Employees
  • LEGN N/A
  • GSAT N/A
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • GSAT Telecommunications Equipment
  • Sector
  • LEGN Health Care
  • GSAT Consumer Discretionary
  • Exchange
  • LEGN Nasdaq
  • GSAT Nasdaq
  • Market Cap
  • LEGN 6.3B
  • GSAT 5.7B
  • IPO Year
  • LEGN 2020
  • GSAT 2006
  • Fundamental
  • Price
  • LEGN $32.30
  • GSAT $42.28
  • Analyst Decision
  • LEGN Strong Buy
  • GSAT Strong Buy
  • Analyst Count
  • LEGN 12
  • GSAT 4
  • Target Price
  • LEGN $70.82
  • GSAT $49.00
  • AVG Volume (30 Days)
  • LEGN 1.5M
  • GSAT 1.2M
  • Earning Date
  • LEGN 11-11-2025
  • GSAT 11-04-2025
  • Dividend Yield
  • LEGN N/A
  • GSAT N/A
  • EPS Growth
  • LEGN N/A
  • GSAT N/A
  • EPS
  • LEGN N/A
  • GSAT N/A
  • Revenue
  • LEGN $796,838,000.00
  • GSAT $260,664,000.00
  • Revenue This Year
  • LEGN $70.27
  • GSAT $7.93
  • Revenue Next Year
  • LEGN $50.28
  • GSAT $11.32
  • P/E Ratio
  • LEGN N/A
  • GSAT N/A
  • Revenue Growth
  • LEGN 74.75
  • GSAT 14.85
  • 52 Week Low
  • LEGN $27.34
  • GSAT $15.45
  • 52 Week High
  • LEGN $47.79
  • GSAT $47.44
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 45.99
  • GSAT 52.98
  • Support Level
  • LEGN $31.44
  • GSAT $41.46
  • Resistance Level
  • LEGN $32.59
  • GSAT $46.39
  • Average True Range (ATR)
  • LEGN 1.36
  • GSAT 2.63
  • MACD
  • LEGN 0.11
  • GSAT -0.70
  • Stochastic Oscillator
  • LEGN 37.97
  • GSAT 25.72

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About GSAT Globalstar Inc.

Globalstar Inc is a telecommunications company that derives revenue from the provision of mobile satellite services. Mobile satellite services are typically used by customers where existing terrestrial wireline and wireless communications networks are impaired or do not exist. The company provides communications services such as two-way voice and data transmission. In addition, one-way data transmission is also offered. Both services are offered using mobile or fixed devices. The company is an owner of satellite assets. It has one reportable segment: MSS business. The company generates the vast majority of its revenue within the United States.

Share on Social Networks: